Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy - Wikidata - wikimedia - TriplyDB

Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy

Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy

http://www.wikidata.org/entity/Q42321927

about

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis.Neopterin and Cardiovascular Events Following Coronary Stent Implantation in Patients with Stable Angina Pectoris

P2860

Q42321928-7B0F8D5E-D6B0-47E9-A686-9BFD79BD6DD9 Q58701059-0704522F-E587-45D0-B7BD-5D5FF0032E57

P2860

Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy

http://www.wikidata.org/entity/Q42321927

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@en

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@nl

type

label

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@en

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@nl

prefLabel

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@en

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@nl

P1433

Q42321927-43443C1F-EBA3-41A3-B6E8-4A34504324DD

P1476

Q42321927-C5D1656E-DF6D-409A-BE43-9E046FA4ACED

P2093

Q42321927-0367A65C-2AA4-4DEC-BE1D-135215AB8004

Q42321927-307ED2DA-2CF8-459E-85A0-3E6B9DE12FBC

Q42321927-3B71AC47-D82F-458D-A81A-929BF8908C42

Q42321927-3FDE0277-45FC-4751-9D4D-85B203983925

Q42321927-51077E02-080E-4ED4-95DC-C955B733B333

Q42321927-92398449-078A-4AB7-8BDA-18F96148152C

Q42321927-A3CCFA37-19A1-408A-A7D8-9B5AD7B53510

Q42321927-C58324B6-39CB-4220-BC32-63945F362135

Q42321927-E61DA814-8BC8-4D81-8FB2-E2B1EE0FFFCE

P2860

Q42321927-09139172-42EF-4ACE-90DF-FB47EADDF87A

Q42321927-0EAB2F4C-1664-4D25-B07A-C3775592ADE5

Q42321927-10BAA311-48A5-4510-8023-64F60064F2EB

Q42321927-1BBF776E-2253-4804-9620-5476F58E0119

Q42321927-2385E7FE-1A7F-4DE5-860A-50DFBEF23494

Q42321927-25471336-A6CD-4A77-BD89-974E04C0C0AF

Q42321927-34E4D34D-895E-411B-BB08-56B9AF30DD03

Q42321927-4E06A488-C63E-40A4-8C68-1E47DF842796

Q42321927-50EE6353-B1F5-4A1E-B95F-62B75AF2BDFC

Q42321927-63D83292-99FD-4EE9-A983-E640A1D70F29

P304

Q42321927-6AFFEDEF-BCFA-47AB-9FE9-D8F442B6C99D

P31

Q42321927-F61270B8-F2FF-4B81-95B7-CA446F9FF5D5

P356

Q42321927-B1C4C231-1969-4068-BCC7-AF040DD18E81

P433

Q42321927-4DB16C86-5161-482E-9D65-FB1BA8F8058A

P478

Q42321927-3F25B5E7-6D6B-4702-9AE2-92CAD25EA217

P577

Q42321927-AD075D21-C8F3-4B72-B3E6-C6914691D96B

P698

Q42321927-C0245A45-168B-4C21-8D75-2B7429F0A7EC

P921

Q42321927-0CA182AB-D280-4051-99F8-A05539F637D9

Q42321927-4FCA4130-9666-4B32-8AEE-4D1A4F675847

P932

Q42321927-52EEAD75-0F30-4EB9-B63E-651CCD51369F

P356

P1433

Journal of atherosclerosis and thrombosis

P1476

Enhanced Impact of Cholesterol ...... rvention During Statin Therapy

@en

P2093

Ken-Ichi Hirata

http://www.w3.org/2001/XMLSchema#string

Kenta Mori

http://www.w3.org/2001/XMLSchema#string

Masakazu Shinohara

http://www.w3.org/2001/XMLSchema#string

Ryuji Toh

http://www.w3.org/2001/XMLSchema#string

Shigeyasu Tsuda

http://www.w3.org/2001/XMLSchema#string

Tatsuro Ishida

http://www.w3.org/2001/XMLSchema#string

Tetsuya Hara

http://www.w3.org/2001/XMLSchema#string

Toshihiko Oshita

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Irino

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Inactivating mutations in NPC1L1 and protection from coronary heart disease

Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD.

P304

123-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5551/JAT.32615

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27487947

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

5305673

http://www.w3.org/2001/XMLSchema#string